Company Overview
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Why Investors Should Care
Generates a return on equity of 44.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 35.8%.
Net profit has compounded at 47.6% per year over the last five years.
Revenue has grown at a 17.4% CAGR over the past five years.
Trades at a P/E of 18.1, below the sector median of 24.8.
Maintains a net profit margin of 35.3%.
Recent Developments
- Jan 2026 Revenue of $2.32B (+7.0% YoY); net profit $782.57M.
- Trailing 12 Months Year-on-year growth — revenue +10.6%, earnings +26.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.4%, profit CAGR 47.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.40% |
| 1 Year: | 10.60% |
Compounded Profit Growth
| 5 Years: | 47.58% |
| 1 Year: | 26.20% |
Stock Price Performance
| 1 Year: | +49.83% |
| 6 Months: | +36.11% |
| 3 Months: | +11.46% |
| 1 Month: | +6.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.36 · Neutral
P/E of 18.14 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 44.4%.
- Healthy ROCE of 35.8%.
- Excellent profit margin of 35.3%.
- Compounding revenue at 17.4% over 5 years.
- Profit CAGR of 47.6% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EXEL Exelixis, Inc. R3KPHARMA | 57.67 | 18.14 | $14.29B | 0.00% | 35.76% | 44.39% | 17.40% | 47.58% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2015 | Mar 2016 | Apr 2016 | Jun 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Apr 2025 | Jul 2025 | Oct 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 80.89M | 99.01M | 152.51M | 120.07M | 213.72M | 186.11M | 225.40M | 228.60M | 215.49M | 240.28M | 271.70M | 240.31M | 226.91M | 259.48M | 231.09M | 270.05M | 270.23M | 385.18M | 328.42M | 355.98M | 419.43M | 411.74M | 408.79M | 469.85M | 471.92M | 425.23M | 637.18M | 539.54M | 555.45M | 568.26M | 597.75M | 610.81M | 628.69M |
| Gross Profit | 8.91M | 8.41M | 8.41M | 30.06M | 30.06M | 40.29M | 50.06M | 65.67M | 84.99M | 91.76M | 91.52M | 128.63M | 139.84M | 155.59M | 168.87M | 172.08M | 186.14M | 184.23M | 184.41M | 184.59M | 169.51M | 159.86M | 191.32M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -31.60M | -49.13M | -49.13M | -25.14M | -25.14M | 7.26M | 38.88M | 20.19M | 27.11M | 81.18M | 37.43M | 116.31M | 85.77M | 125.18M | 111.60M | 84.56M | 91.99M | 115.61M | 77.32M | 52.81M | 75.53M | -42.58M | 24.30M | -4.61M | 123.01M | 51.62M | 83.24M | 83.71M | 82.61M | 28.83M | 77.85M | -17.58M | 29.46M | 275.87M | 136.07M | 186.86M | 213.58M | 236.54M | 251.34M | 248.41M |
| Net Income | -41.57M | -59.22M | -59.22M | -34.84M | -34.84M | -11.28M | 35.12M | 16.70M | 17.66M | 81.38M | 38.49M | 115.86M | 87.49M | 126.63M | 360.09M | 75.78M | 79.04M | 97.45M | 68.74M | 48.61M | 66.82M | -32.04M | 28.39M | 1.60M | 96.09M | 38.20M | 68.57M | 70.67M | 73.21M | 40.03M | 81.18M | 1.04M | 37.32M | 226.12M | 117.97M | 159.62M | 184.85M | 193.58M | 210.47M | 212.05M |
| Diluted EPS | - | -0.26 | -0.26 | -0.15 | -0.15 | -0.04 | 0.12 | 0.05 | 0.06 | 0.26 | 0.12 | 0.37 | 0.28 | 0.41 | 1.15 | 0.24 | 0.25 | 0.31 | 0.22 | 0.15 | 0.21 | -0.10 | 0.09 | 0.00 | 0.30 | 0.12 | 0.21 | 0.22 | 0.23 | 0.12 | 0.25 | 0.00 | 0.12 | 0.77 | 0.40 | 0.55 | 0.65 | 0.69 | 0.79 | 0.82 |
| R&D Expense | - | 28.93M | - | 22.98M | - | 20.26M | - | 23.21M | 28.21M | 28.54M | - | 37.76M | 42.49M | 44.74M | - | 63.29M | 81.93M | 97.30M | - | 101.88M | 114.93M | 176.76M | - | 159.29M | 148.79M | 163.37M | 156.67M | 199.48M | 198.84M | 234.25M | 232.57M | 332.58M | 227.69M | 211.15M | 222.57M | 212.23M | 200.36M | 199.16M | 199.92M | 211.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 151.76M | 185.04M | 289.64M | 47.45M | 31.34M | 25.11M | 37.17M | 37.17M | 191.45M | 452.48M | 853.83M | 967.77M | 987.54M | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Operating Income | -121.91M | -91.40M | 89.53M | -122.44M | -200.73M | -224.46M | -121.42M | -121.42M | -28.12M | 165.91M | 438.86M | 369.47M | 110.06M | 286.67M | 201.48M | 170.88M | 604.62M | 872.19M |
| Net Income | -135.22M | -92.33M | 75.70M | -145.34M | -238.19M | -261.30M | -161.74M | -161.74M | -70.22M | 154.23M | 690.07M | 321.01M | 111.78M | 231.06M | 182.28M | 207.76M | 521.27M | 782.57M |
| Diluted EPS | -1.26 | -0.85 | 0.58 | -0.92 | -1.33 | - | - | -0.77 | -0.28 | 0.49 | 2.21 | 1.02 | 0.35 | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| R&D Expense | 234.70M | 210.68M | 156.84M | 128.88M | 178.76M | 189.10M | 96.35M | 96.35M | 95.97M | 112.17M | 182.26M | 336.96M | 547.85M | 693.72M | 891.81M | 1.04B | 910.41M | 825.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Jan 2015 | Dec 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 360.79M | 393.26M | 721.10M | 503.29M | 323.27M | - | 332.34M | - | 595.74M | 655.29M | 1.42B | 1.89B | 2.14B | 2.62B | 3.07B | 2.94B | 2.95B | 2.84B |
| Total Equity | -56.26M | -163.72M | -228.32M | 90.63M | 238.13M | 14.50M | -159.32M | -159.32M | -140.81M | -140.81M | 89.32M | 284.96M | 1.29B | 1.69B | 1.88B | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B |
| Cash & Equivalents | 247.70M | 86.80M | 97.44M | 74.26M | 170.07M | 103.98M | 80.39M | 80.39M | 141.63M | 141.63M | 151.69M | 183.16M | 314.77M | 266.50M | 319.22M | 647.17M | 501.19M | 262.99M | 217.37M | 482.49M |
| Long Term Debt | - | - | 170.71M | 176.65M | 322.57M | 335.48M | 259.13M | - | 417.94M | - | 0 | 0 | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 589.12M | 302.63M | 476.01M | 483.45M | 482.59M | - | 473.15M | - | 506.42M | 370.33M | 134.83M | 199.70M | 258.22M | 405.62M | 583.06M | 678.45M | 703.49M | 683.10M |
| Current Liabilities | - | - | 199.94M | 92.33M | 81.70M | 87.85M | 170.43M | - | 52.25M | - | 268.79M | 115.17M | 105.47M | 142.75M | 204.66M | 337.59M | 324.36M | 394.28M | 403.77M | 405.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.59M | -101.05M | -159.23M | -123.15M | -198.77M | -235.41M | -141.59M | -141.05M | 210.40M | 165.61M | 415.72M | 526.96M | 208.98M | 400.80M | 362.61M | 333.32M | 699.97M | 884.27M |
| Investing Cash Flow | -112.32M | -19.57M | -51.46M | -259.47M | 144.35M | 146.33M | 50.08M | 50.08M | -214.55M | 36.80M | -297.85M | -587.25M | -131.22M | -42.88M | -524.41M | -26.95M | -116.78M | 350.44M |
| Financing Cash Flow | -33.99M | 131.26M | 187.51M | 478.43M | -11.67M | 65.49M | 152.75M | 152.21M | 15.70M | -169.93M | 9.69M | 12.55M | -25.13M | -14.80M | 586.00K | -546.05M | -628.81M | -969.59M |
| Capital Expenditure | -5.91M | -1.81M | -991.00K | -2.72M | -2.17M | -474.00K | -447.00K | -447.00K | -1.70M | -21.14M | -33.30M | -12.83M | -30.34M | -54.23M | -27.71M | -40.47M | -28.43M | -8.43M |
| Free Cash Flow | -20.50M | -102.86M | -160.22M | -125.86M | -200.94M | -235.88M | -142.03M | -141.50M | 208.70M | 144.47M | 382.42M | 514.12M | 178.64M | 346.58M | 334.91M | 292.86M | 671.54M | 875.84M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 550.38M | 652.03M | 947.51M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -80.3% | -49.4% | 30.9% | -258.0% | -640.5% | -893.9% | -326.6% | -326.6% | -14.7% | 36.7% | 51.4% | 38.2% | 11.1% | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Net Margin % | -89.1% | -49.9% | 26.1% | -306.3% | -760.1% | -1,040.6% | -435.1% | -435.1% | -36.7% | 34.1% | 80.8% | 33.2% | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| ROE % | 82.6% | 40.4% | 83.5% | -61.0% | -1,642.9% | 164.0% | 114.9% | 114.9% | -78.6% | 54.1% | 53.6% | 19.0% | 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% |
| ROCE % | - | -56.8% | 29.8% | -19.1% | -48.3% | -146.9% | -43.4% | - | -8.6% | 30.7% | 33.3% | 21.2% | 5.7% | 12.6% | 7.3% | 6.7% | 23.8% | 35.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.73% | 29.08M | $1.70B |
| 2 | Farallon Capital Management LLC | 5.44% | 13.47M | $785.99M |
| 3 | Renaissance Technologies, LLC | 5.42% | 13.43M | $783.66M |
| 4 | Vanguard Portfolio Management LLC | 4.86% | 12.04M | $702.84M |
| 5 | AQR Capital Management, LLC | 4.45% | 11.02M | $643.36M |
| 6 | Vanguard Capital Management LLC | 4.42% | 10.95M | $639.10M |
| 7 | State Street Corporation | 4.02% | 9.97M | $581.85M |
| 8 | Fuller & Thaler Asset Management Inc. | 3.60% | 8.93M | $521.12M |
| 9 | LSV Asset Management | 3.29% | 8.15M | $475.43M |
| 10 | Geode Capital Management, LLC | 3.09% | 7.65M | $446.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EXEL
Exelixis Stock Price Forecast. Should You Buy EXEL? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE84NUxWVngyXzdqZnhUbi1IRVpTUXZKSUpuQ0FtdE5pU0t5U0pWQ25xUHM1bll5aHZMWExhd1hBanJaVmk0RU5fQg?oc=5" target="_blank">Exelixis Stock Price Forecast. Should You Buy EXEL?</a> <f…
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOcjJZWXhzMEtmVmdFVy1wRHVOVnlhVFhUa1BPZ2FhcTJYTWlPYnJVMW1wXzg0ZTRFUGNqNzdYSDVybDMxYnN2SXRuTnZaY0JUQWVRODJZcDdzQ0hBcHFvVlFRM2N0OWlkaVprbXN3cVdMcVBDdnBSUHZyUHdWS3NVZE80aFEwSEJfa0JDLU…
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQcDJsV1c2UkFINnZNM1JucS15Y2dDYl8yYzV3TGJQT1FsNnA3RGJIYXBhRFZsS0xGSXAzR0VOVU5fRTI2cXdIbXZSRUNKd0J1eEdyQ2JvNzZGOHNSZFYtX0VfWmVOTzQ4TGhpYjIwUUVicENERXR3ZDNVUEhjWW5WZVp5QUlTejhYRXNVQ1…
Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha? - Trefis
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNTkZ1WVozUXMyVGlfZkJJQWhOTDNxVkdIMm9Hamo4ckt0bnc1QnhCNVpPMUhSYUVwdy1reUI3UFBaVTF0VkVuNkQwUzh4WUpsc2JiQktWeVBsRUlpdDhGbDFmZE9pNUFBVVVNVmk4YmF4WlBqbzZJRFpUTXBWWGN6M0FsYVQzX0I4eXZxR0…
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis - Morningstar
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxNc2VYY1pJZFA0Q1BmY2pzRkVUOUtHMl9YaFJIWHhQTGxEZC1yUXZ6VWpuV1hST2NFZUFPUEJIYnpMVWl5UmM1UVNFTWR2WVViMjZyLUk1MHBnV183Z3FhcTFINHVsclNJZTZDcFM5MktPcjBYUDFaam5tb1I4cjlsYTJ0eUFGY2tMWmxKbF…
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Through Biotechnology with High Return on Equity - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNTUtiTlhDaDZ2RGw4aWlzS3ZuOXh0OXlpN2pYYkNaTWZvZEhlSmVXQzhnM3gtTVZzY1RYNmlVbmVkSHRfb2huU0JRREU1MXN6VHJYejk1U1c1OFFZNHZpT3RaNDNtc3N0R19XMTh3ZDRLYXN6MkM2WWlkM21FMmQtd3MwMERwT2VrYWxKd2…
EXEL — Frequently Asked Questions
What is the current share price of Exelixis, Inc. (EXEL)?
As of 2026-09-19 21:16 PDT, Exelixis, Inc. (EXEL) trades at $57.67 on NasdaqGS. Its 52-week range is $34.54 to $59.13.
What is the market capitalisation of EXEL?
Exelixis, Inc. (EXEL) has a market capitalisation of $14.29B on NasdaqGS.
What is the P/E ratio of EXEL?
EXEL trades at a trailing price-to-earnings (P/E) ratio of 18.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.87.
What is the return on equity (ROE) of EXEL?
EXEL has a return on equity (ROE) of 44.39%. Its return on capital employed (ROCE) is 35.76%.
Is EXEL a good stock to buy?
This page provides a data-driven analysis of Exelixis, Inc. (EXEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.